# GLM Review Validation

- **Source**: user-provided GLM review summary
- **Date**: 2026-07-07
- **Scope checked**: live branch validation against Phases 1-3 artifacts
- **Verdict**: PARTIALLY CONFIRMED

## Confirmed

- The article page adds an extra footer CTA in `src/pages/guides/[slug].astro` (`Try it on your photo ->`) that is not explicitly called out in the Phase 2 article-page intent block. This is real plan drift in a narrow documentation sense, but benign and product-appropriate.
- `src/content.config.ts` currently accepts `cover: z.string()`. A typo such as a missing leading `/` would compile and fail at runtime rather than at schema-validation time. Hardening to `z.string().startsWith("/")` would be a reasonable low-cost reliability improvement.

## Corrected

- The GLM note that `npm run build` was not rerun in this pass is stale against the live review work on 2026-07-07. `npm run build` was rerun on current `HEAD` and passed once sandbox-only Wrangler/AppData and local-network restrictions were removed. The earlier build failures were environment friction, not a product regression.

## Recommendation

- Keep the schema hardening item as the stronger actionable observation.
- Treat the article-footer CTA as plan hygiene only unless the team wants the plan to be exact down to every engagement affordance.

## Resolution (Claude, 2026-07-07)

Both items applied (user decision "apply both"):

- **Schema hardening** — `src/content.config.ts` `cover: z.string()` → `cover: z.string().startsWith("/")`. A missing-leading-slash typo now fails at build-time schema validation instead of rendering a broken `<img>`. All three shipped covers (`/images/guides/*`) already satisfy the guard; `npm run build` reran green and prerendered all three guide pages, confirming no regression.
- **Plan hygiene** — Phase 2 §3 (Article pages) intent block now names the "Try it on your photo →" beam footer CTA, so the plan reads truthfully.

Neither item was a Phase 3 defect (Phase 3 impl-review: APPROVED, 0 findings); both are Phase-2-scoped follow-ups landed alongside the review record.
